Clinical trials on for an advanced oral drug for kala-azar

Mar 06, 2020

Leishmaniasis affects over one billion people; Visceral leishmaniasis(VL) also known as kala-azar is the most serious form of the disease, affects an estimated 50 000 to 90 000 people per year. If left untreated it is almost always fatal. After malaria, it is the second largest parasitic killer in the world. A new oral drug for kala-azar that holds the promise of reduced treatment time and fewer side effects is currently in its first phase of trials in collaboration between the Drugs for Neglected Diseases Initiative (DNDi) and Novartis. The Week


Other news

Cookies help us deliver our services. By using our services, you agree to our use of cookies. What are cookies?